<unk>  has a labeled indication for "short-term (generally <10 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate". Pregnancy Opioids such as hydrocodone cross the placenta, and can therefore affect the fetus. Studies have shown a possible association between opioids and adverse outcomes such as birth defects, poor fetal growth, stillbirth, and preterm delivery. Prolonged use of opioids by a pregnant mother can also lead to neonatal withdrawal syndrome. NSAIDs such as<unk>  should generally be avoided in pregnancy, as there are conflicting reports of birth defects after in utero exposure. However, it is accepted that NSAIDs prevent closure of the fetal ductus arteriosus, which happens during the later stages of pregnancy. Because of this,<unk>  should be avoided after 30 weeks gestation. Breastfeeding Hydrocodone and<unk>  are excreted in breast milk, so appropriate caution should be taken when prescribing to breastfeeding mothers. Special populations There is no evidence to support altered pharmacokinetic properties due to differences in gender or age. However, this drug combination has not been tested in children.
Hydrocodone/ibuprofen
Oxycodone/ibuprofen
Ibuprofen/paracetamol
Hydrocodone/paracetamol
Naproxen/diphenhydramine
Hydrocodone/aspirin
Celecoxib/tramadol
Butalbital/acetaminophen